Talk:Anti-VEGF
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Anti-VEGF.
|
 | It is requested that an image or photograph of Anti-VEGF be included in this article to improve its quality. Please replace this template with a more specific media request template where possible. The Free Image Search Tool or Openverse Creative Commons Search may be able to locate suitable images on Flickr and other web sites. |
(split from Vascular endothelial growth factor) Dec 2015
editUnbalanced - too much on just AMD
editThe large AMD/pricing section may need its own article.
Would be helpful to more clearly list Anti-VEGF drugs that have been approved in USA/Europe etc, and any in phase III trials. Need an update on the potential problems too. - Rod57 (talk) 15:38, 29 January 2016 (UTC)
Merge?
editThis should probably be merged into Angiogenesis inhibitor. And then trimmed a bunch. Jytdog (talk) 13:32, 22 October 2018 (UTC)
Requested move 20 October 2022
edit- The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.
The result of the move request was: Moved. (non-admin closure) Adumbrativus (talk) 03:50, 28 October 2022 (UTC)
Anti–vascular endothelial growth factor therapy → Anti-VEGF – Hi guys, I think it would be good to move this to the shorter title because it's the WP:COMMONNAME, and also for the same reasons why for example we have the article at beta blocker instead of the much longer "beta-adrenergic receptor blockers". Thank you. Dr. Vogel (talk) 22:42, 20 October 2022 (UTC)
- Support this simple move to a common, ordinary abbreviation. The longer name will automatically be preserved as a redirect, so that will help anyone searching under the long name. WhatamIdoing (talk) 00:15, 21 October 2022 (UTC)
- Support the abbreviated version is common and easier for the human brain to process.Draken Bowser (talk) 08:47, 21 October 2022 (UTC)
- Support per nom.--Ortizesp (talk) 15:33, 21 October 2022 (UTC)
- Support common name. Consider Anti-VEGF therapy or Anti-VEGF treatment as name too, although clunkier vs "beta blocker" comparison; proposed move is best imo. --Treetear (talk) 14:27, 25 October 2022 (UTC)
- I also like Treetear's suggestion of including "therapy" or "treatment" in the title. Either works for me. WhatamIdoing (talk) 15:57, 25 October 2022 (UTC)
- I can't think of any reasons why we may want to antagonise VEGF, otherwise than as a treatment. That's why I proposed just "anti-VEGF" instead of something longer. For comparison, we have the BB article at beta blocker, not at beta blocker therapy or beta blocker treatment. Those aren't even redirects! Even beta blockade, which some people do say in real life, is not a redirect. Dr. Vogel (talk) 23:20, 25 October 2022 (UTC)
- We should probably make all of those redirects. As I said, all of these work for me. WhatamIdoing (talk) 23:38, 25 October 2022 (UTC)
- I can't think of any reasons why we may want to antagonise VEGF, otherwise than as a treatment. That's why I proposed just "anti-VEGF" instead of something longer. For comparison, we have the BB article at beta blocker, not at beta blocker therapy or beta blocker treatment. Those aren't even redirects! Even beta blockade, which some people do say in real life, is not a redirect. Dr. Vogel (talk) 23:20, 25 October 2022 (UTC)
- I also like Treetear's suggestion of including "therapy" or "treatment" in the title. Either works for me. WhatamIdoing (talk) 15:57, 25 October 2022 (UTC)